Genentech (Roche) licensed AC Immune's anti-phospho-Tau immunotherapy program for Alzheimer's disease. AC Immune received upfront and near-term payments, with total potential value up to $570M in milestones plus royalties. The collaboration targets phosphorylated tau protein, a key pathological marker in Alzheimer's and other tauopathies.